Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,177 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
ZEB1 suppression sensitizes KRAS mutant cancers to MEK inhibition by an IL17RD-dependent mechanism.
Peng DH, Kundu ST, Fradette JJ, Diao L, Tong P, Byers LA, Wang J, Canales JR, Villalobos PA, Mino B, Yang Y, Minelli R, Peoples MD, Bristow CA, Heffernan TP, Carugo A, Wistuba II, Gibbons DL. Peng DH, et al. Among authors: tong p. Sci Transl Med. 2019 Mar 13;11(483):eaaq1238. doi: 10.1126/scitranslmed.aaq1238. Sci Transl Med. 2019. PMID: 30867319 Free PMC article.
ZEB1 induces LOXL2-mediated collagen stabilization and deposition in the extracellular matrix to drive lung cancer invasion and metastasis.
Peng DH, Ungewiss C, Tong P, Byers LA, Wang J, Canales JR, Villalobos PA, Uraoka N, Mino B, Behrens C, Wistuba II, Han RI, Wanna CA, Fahrenholtz M, Grande-Allen KJ, Creighton CJ, Gibbons DL. Peng DH, et al. Among authors: tong p. Oncogene. 2017 Apr 6;36(14):1925-1938. doi: 10.1038/onc.2016.358. Epub 2016 Oct 3. Oncogene. 2017. PMID: 27694892 Free PMC article.
Stress hormones promote EGFR inhibitor resistance in NSCLC: Implications for combinations with β-blockers.
Nilsson MB, Sun H, Diao L, Tong P, Liu D, Li L, Fan Y, Poteete A, Lim SO, Howells K, Haddad V, Gomez D, Tran H, Pena GA, Sequist LV, Yang JC, Wang J, Kim ES, Herbst R, Lee JJ, Hong WK, Wistuba I, Hung MC, Sood AK, Heymach JV. Nilsson MB, et al. Among authors: tong p. Sci Transl Med. 2017 Nov 8;9(415):eaao4307. doi: 10.1126/scitranslmed.aao4307. Sci Transl Med. 2017. PMID: 29118262 Free PMC article.
A YAP/FOXM1 axis mediates EMT-associated EGFR inhibitor resistance and increased expression of spindle assembly checkpoint components.
Nilsson MB, Sun H, Robichaux J, Pfeifer M, McDermott U, Travers J, Diao L, Xi Y, Tong P, Shen L, Hofstad M, Kawakami M, Le X, Liu X, Fan Y, Poteete A, Hu L, Negrao MV, Tran H, Dmitrovsky E, Peng D, Gibbons DL, Wang J, Heymach JV. Nilsson MB, et al. Among authors: tong p. Sci Transl Med. 2020 Sep 2;12(559):eaaz4589. doi: 10.1126/scitranslmed.aaz4589. Sci Transl Med. 2020. PMID: 32878980 Free PMC article.
An Integrated Molecular Analysis of Lung Adenocarcinomas Identifies Potential Therapeutic Targets among TTF1-Negative Tumors, Including DNA Repair Proteins and Nrf2.
Cardnell RJ, Behrens C, Diao L, Fan Y, Tang X, Tong P, Minna JD, Mills GB, Heymach JV, Wistuba II, Wang J, Byers LA. Cardnell RJ, et al. Among authors: tong p. Clin Cancer Res. 2015 Aug 1;21(15):3480-91. doi: 10.1158/1078-0432.CCR-14-3286. Epub 2015 Apr 15. Clin Cancer Res. 2015. PMID: 25878335 Free PMC article.
Co-occurring genomic alterations define major subsets of KRAS-mutant lung adenocarcinoma with distinct biology, immune profiles, and therapeutic vulnerabilities.
Skoulidis F, Byers LA, Diao L, Papadimitrakopoulou VA, Tong P, Izzo J, Behrens C, Kadara H, Parra ER, Canales JR, Zhang J, Giri U, Gudikote J, Cortez MA, Yang C, Fan Y, Peyton M, Girard L, Coombes KR, Toniatti C, Heffernan TP, Choi M, Frampton GM, Miller V, Weinstein JN, Herbst RS, Wong KK, Zhang J, Sharma P, Mills GB, Hong WK, Minna JD, Allison JP, Futreal A, Wang J, Wistuba II, Heymach JV. Skoulidis F, et al. Among authors: tong p. Cancer Discov. 2015 Aug;5(8):860-77. doi: 10.1158/2159-8290.CD-14-1236. Epub 2015 Jun 11. Cancer Discov. 2015. PMID: 26069186 Free PMC article.
A Patient-Derived, Pan-Cancer EMT Signature Identifies Global Molecular Alterations and Immune Target Enrichment Following Epithelial-to-Mesenchymal Transition.
Mak MP, Tong P, Diao L, Cardnell RJ, Gibbons DL, William WN, Skoulidis F, Parra ER, Rodriguez-Canales J, Wistuba II, Heymach JV, Weinstein JN, Coombes KR, Wang J, Byers LA. Mak MP, et al. Among authors: tong p. Clin Cancer Res. 2016 Feb 1;22(3):609-20. doi: 10.1158/1078-0432.CCR-15-0876. Epub 2015 Sep 29. Clin Cancer Res. 2016. PMID: 26420858 Free PMC article.
KDR Amplification Is Associated with VEGF-Induced Activation of the mTOR and Invasion Pathways but does not Predict Clinical Benefit to the VEGFR TKI Vandetanib.
Nilsson MB, Giri U, Gudikote J, Tang X, Lu W, Tran H, Fan Y, Koo A, Diao L, Tong P, Wang J, Herbst R, Johnson BE, Ryan A, Webster A, Rowe P, Wistuba II, Heymach JV. Nilsson MB, et al. Among authors: tong p. Clin Cancer Res. 2016 Apr 15;22(8):1940-50. doi: 10.1158/1078-0432.CCR-15-1994. Epub 2015 Nov 17. Clin Cancer Res. 2016. PMID: 26578684 Free PMC article.
Epithelial-Mesenchymal Transition Predicts Polo-Like Kinase 1 Inhibitor-Mediated Apoptosis in Non-Small Cell Lung Cancer.
Ferrarotto R, Goonatilake R, Yoo SY, Tong P, Giri U, Peng S, Minna J, Girard L, Wang Y, Wang L, Li L, Diao L, Peng DH, Gibbons DL, Glisson BS, Heymach JV, Wang J, Byers LA, Johnson FM. Ferrarotto R, et al. Among authors: tong p. Clin Cancer Res. 2016 Apr 1;22(7):1674-1686. doi: 10.1158/1078-0432.CCR-14-2890. Epub 2015 Nov 23. Clin Cancer Res. 2016. PMID: 26597303 Free PMC article.
1,177 results